MarketPeel
Insider Trading Intelligence
ER

Eric I. Richman

GANX
CHIEF EXECUTIVE OFFICER · GAIN THERAPEUTICS, INC. · CIK 0001313876
FILING MIX · LIFETIME93%/7%
BUYS
14
SELLS
1
TOTAL VALUE
$141.5K
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
59,030
AVG SELL PX
TRADE KIND
SHOWING 15 / 15
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Eric I. Richman, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+66.67%+2.47%+2.91%-0.44%-1.82%
14d6+100.00%+16.93%+3.86%+13.07%+8.64%
30d6+66.67%+18.36%-1.76%+20.12%+20.04%
60d6+50.00%+20.08%+1.06%+19.02%+15.99%
90d6+100.00%+40.26%+6.75%+33.50%+32.19%
180d6+83.33%+18.57%+4.08%+14.49%+13.28%
1y6+83.33%+45.00%+8.48%+36.52%+46.84%
2y6+33.33%+14.67%+32.22%-17.55%-44.49%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
GANX · 15,000 shares · as of Jun 24, 2025
082,350164,700247,050329,4002022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
FLOW · 14 buys / 1 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 24, 2025Jun 25, 2025View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
5,000$1.23$6.2K277,629Jul 1, 2024Jul 1, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
12,000$1.21$14.5K289,629Jul 1, 2024Jul 1, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 24, 2024Jun 26, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
54,900272,629Sep 20, 2023Sep 22, 2023View →
GANX
GAIN THERAPEUTICS, INC.
SALE
54,9000Sep 20, 2023Sep 22, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
329,400329,400Sep 20, 2022Sep 22, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
54,90054,900Sep 20, 2022Sep 22, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
2,482$2.58$6.4K217,729May 25, 2022May 27, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
9,256$2.83$26.2K215,247May 20, 2022May 23, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
4,000$2.71$10.8K205,991May 19, 2022May 23, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
4,922$7.87$38.7K216,820Aug 16, 2021Apr 21, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
4,922$7.87$38.7K216,820Aug 16, 2021Aug 17, 2021View →
ADMA
ADMA BIOLOGICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Feb 28, 2020Mar 3, 2020View →
ADMA
ADMA BIOLOGICS, INC.
PURCHASEGRANT
Stock grant
7,50044,030Feb 28, 2020Mar 3, 2020View →
Other insiders · GANX
Loading peer insiders…
About this filer
CIK 0001313876
ROLE
CHIEF EXECUTIVE OFFICER
PRIMARY
GANX
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001313876DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback